Literature DB >> 18651103

Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics.

Aru Narendran1, Lucas Coppes, Aarthi Jayanthan, Michael Coppes, Bijan Teja, Delphine Bernoux, David George, Douglas Strother.   

Abstract

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant central nervous system neoplasm that usually affects infants and young children. In this report, we describe culture conditions that enabled the sustained growth of tumor cells obtained from the cerebrospinal fluid (CSF) of an infant with AT/RT. These cells retained the morphological and biomarker characteristics of the original tumor. A screening of receptor tyrosine kinases identified the presence of phosphorylated ErbB4, Insulin-R, PDGFR and IGF-IR, which appear to depend on Hsp90 to maintain their active form. IGF-IR activity is consistent with data from other established AT/RT cell lines. Inhibition of IGF-IR by the small molecular weight inhibitor AEW541 led to growth suppression of cultured AT/RT cells. In addition, neutralizing antibodies to IGF-II also inhibited the growth of these cells suggesting a potential autocrine function for this cytokine. We also compared cultured AT/RT cells to established cell lines to identify consistent drug sensitivity patterns among these cells. In addition to previously described cell lines and xenograft models, continuous culture of CSF derived cells may also provide an effective way to study the biology of AT/RT and to identify potential targets for future therapeutics for this tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651103     DOI: 10.1007/s11060-008-9653-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  46 in total

1.  Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors.

Authors:  S Ogino; S Kubo; F W Abdul-Karim; M L Cohen
Journal:  Pediatr Dev Pathol       Date:  2001 Jan-Feb

2.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Authors:  Paul Haluska; Joan M Carboni; David A Loegering; Francis Y Lee; Mark Wittman; Mark G Saulnier; David B Frennesson; Kimberly R Kalli; Cheryl A Conover; Ricardo M Attar; Scott H Kaufmann; Marco Gottardis; Charles Erlichman
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor.

Authors:  J A Biegel; B Fogelgren; L M Wainwright; J Y Zhou; H Bevan; L B Rorke
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

4.  Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice.

Authors:  C J Guidi; A T Sands; B P Zambrowicz; T K Turner; D A Demers; W Webster; T W Smith; A N Imbalzano; S N Jones
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

5.  Different release of cytokines into the cerebrospinal fluid following surgery for intra- and extra-axial brain tumours.

Authors:  C Woiciechowsky; K Asadullah; D Nestler; F Glöckner; P N Robinson; H D Volk; S Vogel; W R Lanksch
Journal:  Acta Neurochir (Wien)       Date:  1997       Impact factor: 2.216

Review 6.  Chaperoning oncogenes: Hsp90 as a target of geldanamycin.

Authors:  L Neckers
Journal:  Handb Exp Pharmacol       Date:  2006

7.  Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Authors:  John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

8.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.

Authors:  P L Tazzari; G Tabellini; R Bortul; V Papa; C Evangelisti; T Grafone; G Martinelli; J A McCubrey; A M Martelli
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

Review 9.  Heat shock protein 90: the cancer chaperone.

Authors:  Len Neckers
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

10.  Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells.

Authors:  J D'cunja; T Shalaby; P Rivera; A von Büren; R Patti; F L Heppner; A Arcaro; L B Rorke-Adams; P C Phillips; M A Grotzer
Journal:  Eur J Cancer       Date:  2007-04-18       Impact factor: 9.162

View more
  11 in total

1.  Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT/RT).

Authors:  Kyu-Won Shim; Guifa Xi; Barbara-Mania Farnell; Dong-Seok Kim; Takao Tsurubuchi; Tadanori Tomita; C Shekhar Mayanil
Journal:  Childs Nerv Syst       Date:  2013-04-28       Impact factor: 1.475

2.  Atypical teratoid/rhabdoid tumor with hereditary multiple exostoses in an 18-year-old male: A case report.

Authors:  Qian Wu; B O Xiao; L I Li; L I Feng
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

3.  Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents.

Authors:  Umberto Banderali; Aarthi Jayanthan; Kimberley A Hoeksema; Aru Narendran; Wayne R Giles
Journal:  J Neurooncol       Date:  2011-10-05       Impact factor: 4.130

4.  Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

Authors:  Rintaro Hashizume; Nalin Gupta; Mitchel S Berger; Anu Banerjee; Michael D Prados; Jennifer Ayers-Ringler; C David James; Scott R VandenBerg
Journal:  Neuro Oncol       Date:  2010-01-11       Impact factor: 12.300

5.  Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Authors:  Anjali Singh; Xueqing Lun; Aarthi Jayanthan; Halah Obaid; Yibing Ruan; Douglas Strother; Susan N Chi; Amy Smith; Peter Forsyth; Aru Narendran
Journal:  Mol Oncol       Date:  2013-01-11       Impact factor: 6.603

6.  Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.

Authors:  Xueqing Lun; Yibing Ruan; Aarthi Jayanthan; David J Liu; Anjali Singh; Tanya Trippett; John Bell; Peter Forsyth; Randal N Johnston; Aru Narendran
Journal:  Mol Oncol       Date:  2013-06-14       Impact factor: 6.603

7.  Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.

Authors:  Cody L Weston; Michael J Glantz; James R Connor
Journal:  Fluids Barriers CNS       Date:  2011-03-03

8.  Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review.

Authors:  Nicole A Shonka; Terri S Armstrong; Sujit S Prabhu; Amanda Childress; Shauna Choi; Lauren A Langford; Mark R Gilbert
Journal:  J Clin Med Res       Date:  2011-04-04

9.  Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.

Authors:  Aarthi Jayanthan; Delphine Bernoux; Pinaki Bose; Karl Riabowol; Aru Narendran
Journal:  Cancer Cell Int       Date:  2011-12-29       Impact factor: 5.722

10.  Atypical teratoid rhabdoid tumor: current therapy and future directions.

Authors:  Kevin F Ginn; Amar Gajjar
Journal:  Front Oncol       Date:  2012-09-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.